←
Elixir Medical Corp473 posts
Elixir Medical Corp avatar

Elixir Medical Corp

@ElixirMed

Innovation for Life. Elixir Medical is committed to transforming care for patients with heart and vascular disease through innovation.

◷ Joined July 2015▧ 386 Photos and videos
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Nov 10

Elixir Medical will join the interventional cardiology community at TOBI - Complex PCI Course , November 11–13 in Milan, Italy! Don't miss the LithiX™ Hertz Contact Intravascular Lithotripsy presentation on November 11! 📅 Wednesday, November 11 | 7:03–7:15 PM 📍 Main Hall (Magnolia) Session: Complex PCI Toolbox: Devices, Strategies and Real-World Evidence Presentation: The LithiXBalloon: A Novel Mechanism to Fragment Calcium Without an External Energy Source. First Experience in Germany Presenter: Dr. Massimiliano Fusaro Also featured at TOBI 2026: A LithiX live case from Humanitas Research Hospital, offering attendees an opportunity to see Hertz Contact IVL in a real-world clinical setting. Join these sessions to learn from real-world experience how LithiXHC-IVL creates deep, wide cracks in lesions with eccentric, concentric, or nodular calcium without damaging soft tissue Explore the TOBI 2026 program: tobicongress.com/ #TOBI2026 #ElixirMedical #LithiX#HCIVL #ComplexPCI #InterventionalCardiology #CalciumModification The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

0:12
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Nov 3

Clinical insights & expert case reviews from TCT 2026. During “Restoring Vessel Compliance for Long-term PCI Success: The Innovator’s Toolbox,” leading interventional cardiologists shared perspectives on: • Restoring vessel compliance for long-term PCI success • Treating complex coronary calcium across morphologies with the versatile LithiX™ HC-IVL system • Restoring natural vessel function with DynamX® bioadaptor for long-term improved patient outcomes • Combining lesion preparation and vessel restoration in PCI Thank you to our distinguished faculty for sharing their expertise: @DavidErlinge, @valeriaparadies, Krishnaraj Rathod, Tamil Selvan Muthusamy, & Johan Bennett #TCT2026 #ElixirMedical #Bioadaptor #LithiX #PCI #ClinicalData The LithiX HC-IVL system and the DynamX® Coronary Bioadaptor System are CE mark approved and are not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

0:08
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Nov 3

At TCT 2026, @DrAlexandreAbiz presented a three-year update from the DESyne BDS Plus randomized clinical trial that continued to show significantly lower event rates, including for TV-MI and stent thrombosis, for the innovative TRx site-specific antithrombotic therapy arm compared to the control DES: •3.1% v 12.1% TLF rate through 3 years (log-rank p=0.016) •0 Definite/Probable Stent Thrombosis with TRx •Landmark Analysis from Hospital Discharge: Sustained freedom from TLF with TRx in ACS subgroup The outcomes demonstrated promising safety and efficacy of the site-specific anti-thrombotic therapy, highlighting its potential to address the bleeding-ischemic risk trade-off in PCI. Explore the three-year update and the clinical evidence behind Elixir Medical's technology: elixirmedical.com/wp-content… #TCT2026 #ElixirMedical #ClinicalEvidence #PCI #Innovation #InterventionalCardiology

Post attachment
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Nov 3

It’s the final day of TCT 2026! It’s been a great meeting filled with conversations from colleagues across the interventional cardiology community. Thank you to everyone who stopped by the Elixir Medical booth to meet our team and discuss the latest in interventional cardiology. Don’t forget, it’s your last chance to grab popcorn! Stop by Booth #4319 before TCT comes to a close. Find Elixir at TCT: elixirmedical.com/ous/tct-20… #TCT2026 #ElixirMedical #DynamX #LithiX #PCI

0:09
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Nov 2

Clinical evidence from the Bio-RESTORE prospective, multicenter, global post-market study was presented today, adding to the large and growing body of evidence supporting bioadaptor technology and vessel restoration following PCI. Giuseppe M. Sangiorgi shared real-world evidence supporting favorable bioadaptor performance through 12-month follow-up, including in patients with complex clinical and lesion characteristics. •99.6% procedural success‡ •Low 1.6% TLF rate through 12 months •Low 0.5% TLF rate from 6 to 12 months (Landmark Analysis) The latest findings further extend bioadaptor evidence into real-world PCI as robust and durable outcomes continue to build across studies and patient populations. Review the presentation: elixirmedical.com/wp-content… #TCT2026 #ElixirMedical #BioRESTORE #Bioadaptor #DynamX #PCI #ClinicalEvidence ‡ Final residual stenosis <30% without device deficiency and without TLF through hospital discharge The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

Post attachment
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Nov 2

Tamil Selvan Muthusamy presented 1-year outcomes from the MY-IVL Study today at TCT 2026, providing real-world evidence supporting the use of LithiX™ Hertz Contact IVL for coronary calcium modification in patients with complex clinical and lesion characteristics. Highlights included: •113.7% mean stent expansion •5.9% 12-month TLF •Zero device-related events reported Explore the latest LithiX research and more from TCT 2026: elixirmedical.com/wp-content… #TCT2026 #LithiX #IVL #CalciumModification #PCI #ElixirMedical The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

Post attachment
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Nov 2

New Bioadaptor evidence presented at TCT 2026. Over the weekend, @DavidErlinge presented a patient-level pooled analysis of the INFINITY-SWEDEHEART and BIOADAPTOR RCT randomized controlled trials, examining two-year clinical outcomes following PCI with the DynamX® bioadaptor compared with contemporary DES. The pooled analysis from bioadaptor trials provide the continued randomized evidence to date supporting restoration of vessel function as a novel therapeutic strategy for improving long-term outcomes after PCI. •From 6 to 24 months, bioadaptor demonstrated superiority over DES indicating sustained clinical advantage after the early healing period •Through two years, bioadaptor significantly reduced TLF, with greater treatment benefit observed in clinically important ACS and LAD populations which are at elevated risk of recurrent ischemic events Explore the presentation and more from Elixir Medical at TCT 2026: elixirmedical.com/wp-content… #TCT2026 #ElixirMedical #Bioadaptor #DynamX #PCI #ClinicalEvidence #InterventionalCardiology The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

Post attachment
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Oct 31

Elixir Medical is live at TCT 2026! Stop by Booth #4319 to meet our team and learn more about the DynamX® Coronary Bioadaptor System and LithiX™ Hertz Contact Intravascular Lithotripsy. And while you’re there, enjoy something special this year. Stop by and get an Elixir popcorn bag to snack on while you make your way around the show! 🍿 There’s plenty happening beyond the booth, too. Clinical data, scientific presentations, and our featured symposium are taking place throughout the meeting. See what’s ahead and plan your TCT schedule: elixirmedical.com/ous/tct-20… #TCT2026 #ElixirMedical #DynamX #LithiX #PCI #InterventionalCardiology PMN 3035 Rev A

Post attachment
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Oct 30

TCT 2026 starts tomorrow! Elixir Medical is ready for an exciting meeting in San Diego, with new clinical evidence, scientific presentations, and expert perspectives on the evolving approach to coronary intervention. Want to know where to find us? Download our full session agenda and plan the Elixir presentations you don’t want to miss. View the Full TCT Agenda: elixirmedical.com/wp-content… Explore Elixir at TCT: elixirmedical.com/ous/tct-20… We’ll see you in San Diego! #TCT2026 #ElixirMedical #PCI #Bioadaptor #LithiX The LithiX™ HC-IVL system and DynamX Coronary Bioadaptor System are CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 3034 Rev A

Post attachment
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Oct 27

Don’t miss out on expert insights from leaders in interventional cardiology. Put Elixir Medical’s Symposium on your schedule: Restoring Vessel Compliance for Long-term PCI Success: The Innovator’s Toolbox 📅 Monday, November 2 | 2:00–3:15 PM 📍 World Connect Theater Join a distinguished faculty for a scientific program exploring new approaches to restoring vessel compliance, from calcium modification to vessel restoration, and what that could mean for long-term PCI success. Meet the faculty: @DavidErlinge, @valeriaparadies, Krishnaraj Rathod, Tamil Selvan Muthusamy, & Johan Bennett Pre-register on our website: elixirmedical.com/ous/tct-20… #TCT2026 #ElixirMedical #Bioadaptor #LithiX #PCI #InterventionalCardiology PMN 3033 Rev A

0:14
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Oct 24

Planning your TCT 2026 experience? Start here. We have everything you need to follow Elixir Medical at TCT. Explore our full session agenda, meet the featured faculty, learn more about the DynamX® Coronary Bioadaptor System and LithiX™ Hertz Contact Intravascular Lithotripsy, and find information to help plan your time at the meeting. Explore Elixir at TCT 2026: elixirmedical.com/ous/tct-20… #TCT2026 #ElixirMedical #DynamX #LithiX #PCI #InterventionalCardiology PMN 3032 Rev A

Post attachment
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Oct 22

Elixir Medical is heading to TCT 2026, Oct. 31–Nov. 3 in San Diego! Throughout the meeting, researchers will share new clinical evidence and scientific insights surrounding the DynamX® bioadaptor and the LithiX™ Hertz Contact IVL. The program will also feature Elixir’s Academic Satellite Program Symposium, “Restoring Vessel Compliance for Long-term PCI Success: The Innovator’s Toolbox.” Pre-register for the event, meet the faculty and see what’s ahead: elixirmedical.com/ous/tct-20… #TCT2026 #ElixirMedical #DynamX #Bioadaptor #LithiX #IVL #PCI #InterventionalCardiology PMN 3031 Rev A

Post attachment
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Oct 14

Elixir Medical is looking forward to joining the interventional cardiology community at EUROSWISS CTO 2026, October 15–16 in Basel, Switzerland! Don't miss the live case featuring DynamX® Coronary Bioadaptor during Session 3: The Role of Calcium in CTO PCI. Bioadaptor has a unique mechanism of action. It addresses the shortcomings of DES and BRS with remarkably low clinical event rates that showed a plateau from six months through four-year clinical follow-up. Thursday, October 15 | 13:45–14:15 Live Case 5 from University Hospital of Basel Featured Faculty: Chairman: Felix Woitek Coordinator: @jdinaus Provoker: Nicolas Boudou Director: Alexandru Achim Virtual Proctor: Tomi Kaukonen Digital Moderator: Carlo Zivelonghi Live Case Operators: @AriotiManfredi and @RobertoGarbo1 We look forward to connecting with colleagues in Basel and contributing to the ongoing exchange of clinical knowledge and innovation. Learn more about EUROSWISS CTO 2026: euroswisscto.com/ #EUROSWISSCTO2026 #ElixirMedical #DynamX #Bioadaptor #PCI #InterventionalCardiology The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 3041 Rev A

0:21
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Oct 12

Elixir Medical will be attending @sicigise 2026, the 47th National Congress of the Italian Society of Interventional Cardiology, taking place October 13–16 in Milan, Italy. While you're at GISE, join Elixir Medical for our scientific symposium: Breaking the Calcium Challenge with LithiX™ HC-IVL: The Power of Hertz Contact Force 📅 October 15 | 14:30–15:30 📍 Room Sky 2 The session will bring together expert perspectives on modern PCI strategies, the physics behind LithiX™ HC-IVL, followed by clinical case presentations and discussion. Learn how LithiX HC-IVL accelerates and maximizes lithotripsy outcomes without requiring an external energy console. Featured faculty: Giuseppe M Sangiorgi, @micari_antonio , @ALESSAN41132080 , Marco Contarini, @MarcoPavani01, Daniela Benedetto , Daniele Giannotta Learn more about GISE 2026: gise2026.it/ #GISE2026 #ElixirMedical #LithiX #IVL #CalciumModification #PCI #InterventionalCardiology The LithiX HC-IVL system and the DynamX® Coronary Bioadaptor System are CE mark approved and are not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 3029 Rev A

0:24
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Oct 7

Elixir Medical is looking forward to joining the cardiovascular community at Prevention & Intervention – Central European Summit 2026, October 8–10 in Warsaw, Poland. Bringing together clinicians from across Central Europe, the meeting will feature scientific sessions, case-based learning, hands-on workshops and expert discussion spanning interventional and preventive cardiology. While you're there, join us at our session on Elixir Innovations: 📅 October 9 | 11:30 AM–12:30 PM 📍 Room A The session will explore how the unique mechanism of action in DynamX® Bioadaptor improves long-term PCI outcomes, and how LithiX™ HC-IVL accelerates and maximizes PCI outcomes without requiring an external energy console in calcified coronary lesions. Featured faculty: @ZMehmedbegovic, @HawranekMichal, @Marta33717088, @DrDesperak , @vojtanoff, Paweł Kralisz, Piotr J. Wacinski, Piotr Kubler, Adrian Wlodarczak Elixir will also be featured in these sessions: -Calcified Lesions – What to Use and When -Leaving Nothing Behind – Modern Strategies for Coronary Lesion Treatment Learn more about Prevention & Intervention 2026: prev-interv.com/ #PreventionAndIntervention2026 #ElixirMedical #PCI #InterventionalCardiology #DynamX #Bioadaptor #LithiX #IVL The LithiX HC-IVL system and the DynamX® Coronary Bioadaptor System are CE mark approved and are not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 3028 Rev A

0:24
Elixir Medical Corp avatar
Elixir Medical Corp@ElixirMed·Oct 5

Tackling extreme nodular calcium requires both high modification power and durable deliverability. Dr. Charlotte Trouillet demonstrated a systematic approach to treating a massive, subocclusive, para-ostial calcified nodule along with a distal calcified neo-lesion. Using a single LithiX® HC-IVL catheter, she effectively modified the massive proximal nodule and subsequently delivered the same device distally, even after 10 inflations, to treat additional lesions in the same vessel. Her case underscores LithiX’s exceptional deliverability, ease of use, safety, and proven effectiveness on challenging nodular calcium. View the full presentation here: youtu.be/IhmgwlZpXyQ?si=chKz… #EuroPCR2026 #LithiX #PCI #CalciumModification #Cardiology The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States. CAUTION: Case studies shown are based on individual experiences and results may vary. Results depend on a variety of factors, including patient history, severity of condition, and compliance with instructions. Elixir Medical does not claim that these results demonstrate the safety and effectiveness of the device. PMN 2568 Rev A

1:03